Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend

Regeneron Pharmaceuticals, Inc. (REGN) reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the year-ago period.The upside in the bottom line can be attributed to higher revenues.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi (SNY) for Dupixent, higher Eylea HD and L ...